Home › Compare › ITCI vs EQR

ITCI vs EQR: Dividend Comparison 2026

ITCI yields 1.52% · EQR yields 4.73%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EQR wins by $18.6K in total portfolio value
10 years
ITCI
ITCI
● Live price
1.52%
Share price
$131.87
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.9K
Annual income
$167.32
Full ITCI calculator →
EQR
EQR
● Live price
4.73%
Share price
$58.58
Annual div
$2.77
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.5K
Annual income
$3,819.61
Full EQR calculator →

Portfolio growth — ITCI vs EQR

📍 EQR pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodITCIEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ITCI + EQR cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
ITCI pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ITCI
Annual income on $10K today (after 15% tax)
$128.91/yr
After 10yr DRIP, annual income (after tax)
$142.22/yr
EQR
Annual income on $10K today (after 15% tax)
$401.93/yr
After 10yr DRIP, annual income (after tax)
$3,246.67/yr
At 15% tax rate, EQR beats the other by $3,104.45/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ITCI + EQR for your $10,000?

ITCI: 50%EQR: 50%
100% EQR50/50100% ITCI
Portfolio after 10yr
$31.2K
Annual income
$1,993.46/yr
Blended yield
6.40%
📊

Analyst Conviction Gap

Where Wall Street is split right now

ITCI
Analyst Ratings
14
Buy
9
Hold
Consensus: Buy
Price Target
$98.50
-25.3% upside vs current
Range: $70.00 — $132.00
Altman Z
38.0
Piotroski
2/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+20.1% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ITCI buys
0
EQR buys
0
No recent congressional trades found for ITCI or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricITCIEQR
Forward yield1.52%4.73% ✓
Annual dividend / share$2.00$2.77 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8% ✓
Portfolio after 10y$21.9K$40.5K ✓
Annual income after 10y$167.32$3,819.61 ✓
Total dividends collected$1.6K$16.9K ✓
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyHold
Analyst price target$98.50 ✓$70.35

Year-by-year: ITCI vs EQR ($10,000, DRIP)

YearITCI PortfolioITCI Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$10,852$151.66$11,248$547.57$396.00 → EQR
2$11,765$153.81$12,701$666.53$936.00 → EQR
3$12,745$155.85$14,405$814.59$1.7K → EQR
4$13,794$157.78$16,413$999.84$2.6K → EQR
5$14,920$159.61$18,795$1,232.92$3.9K → EQR
6$16,125$161.33$21,639$1,527.95$5.5K → EQR
7$17,417$162.96$25,057$1,903.80$7.6K → EQR
8$18,801$164.50$29,197$2,385.87$10.4K → EQR
9$20,283$165.95$34,250$3,008.70$14.0K → EQR
10$21,870$167.32$40,467$3,819.61$18.6K → EQR

ITCI vs EQR: Complete Analysis 2026

ITCI — Stock

Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder; and in additional neuropsychiatric indications, such as sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease and heart failure; ITI-1284-ODT-SL for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

Full ITCI Calculator →

EQR — REIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this ITCI vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ITCI vs SCHDITCI vs JEPIITCI vs OITCI vs KOITCI vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.